The global EPO biomarkers market was valued at USD 65.61 Billion in 2024, driven by the rising incidence of chronic diseases across the globe. The market is anticipated to grow at a CAGR of 5.49% during the forecast period of 2025-2034, with the values likely to reach USD 111.97 Billion by 2034.
Base Year
Historical Year
Forecast Year
The market is driven by the growing prevalence of chronic kidney disease (CDK) and anemia, increased investments into biomarker research and development (R&D), and the growing integration of AI into diagnostics.
The use of EPO biomarkers is transforming early disease detection and personalized medicine. These advancements enhance diagnostic accuracy by leveraging predictive health trends, driving the market’s growth during the forecast period.
North America dominates the market driven by advanced diagnostic technologies and substantial investments in biomarker research in the region. The robust healthcare infrastructure and ongoing advancement in personalized medicine further strengthen its market position.
EPO biomarkers, essential for evaluating erythropoiesis and diagnosing anemia-related disorders, are in growing demand due to the rising prevalence of chronic kidney disease (CKD) and anemia globally. Key growth drivers include advancements in diagnostics, increasing investments in biomarker research, and the integration of AI in biomarker assessment. Additionally, trends such as the expansion of point-of-care testing and applications in oncology are fueling market growth by improving diagnostic accuracy and treatment outcomes.
Rising Incidence of Chronic Kidney Disease Drives Market Growth
The rising prevalence of anemia and chronic kidney disease (CKD) is a major growth driver for the market. According to the Chronic Kidney Disease 2023 report, over 35.5 million U.S. adults (14%) were estimated to have CKD. This significant burden has increased the demand for precise diagnostic tools like EPO biomarkers. As CKD remains a leading cause of anemia, the need for reliable biomarkers continues to propel advancements in diagnostics and personalized medicine.
Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Market Breakup by Application
Market Breakup by End User
Market Breakup by Region
Market Segmentation Based on the Type is Expected to Witness Substantial Growth
Based on the type, the market is segmented into erythropoietin alfa, erythropoietin beta, erythropoietin zeta, erythropoietin theta, and others. Among these, erythropoietin alfa is expected to lead the market due to its widespread use in treating CKD and cancer-related anemia. Its proven therapeutic efficacy and acceptable safety profile across multiple indications have made it the preferred choice among clinicians globally. The increasing adoption of erythropoietin alfa, particularly in developed markets, is anticipated to drive substantial growth and sustain its market dominance throughout the forecast period.
Regionally, the market report offers an insight into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Among these, North America is expected to lead the market due to the high prevalence of chronic kidney disease, increasing cancer cases, and strong investment in biomarker research. The presence of advanced diagnostic laboratories and robust healthcare infrastructure further supports market growth in this region.
The key features of the market report include patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Established in 1849 and based in New York City, USA, it specializes in the development of EPO-related therapies. One of these is Retacrit® (epoetin alfa-epbx) a biosimilar for the treatment of anemia due to chronic kidney disease, cancer, and other conditions. The product portfolio offers biomarker-driven precision medicine approaches to nephrology and oncology.
Established in 1668 and headquartered in Darmstadt, Germany, Merck KGaA is a leading provider of ...
Founded in 1896 and headquartered in Basel, Switzerland, Roche offers the Elecsys® Erythropoi...
Founded in 1952 and headquartered in Hercules, California, USA, Bio-Rad is best known for its Bio...
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other companies include Eve Technologies Inc., Bioagilytix Labs, GenScript Biotech Corporation, Kyowa Kirin Co. Ltd, Siemens Healthineers AG, Amgen Inc., and Biocon Biologics Limited.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Application |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share